U.S. FDA approves Remdesivir for COVID-19

Even though the World Health Organization has published the largest randomized trial showing that remdesivir showed no benefit on reducing hospital stays or mortality, the drug has been approved by the U.S. FDA for standard of care use for hospitalized COVID-19 patients. The approval was based on a study by researchers from Florida Atlantic University’s Schmidt College of Medicine and a collaborator, who reviewed the totality of available evidence to detect the plausible small-to-moderate effects of remdesivir and concluded that the current evidence justifies compassionate use of remdesivir for severely ill patients with COVID-19.